Abstract
In this paper, we estimate two empirical models using a pooled, cross-section sample of international pharmaceutical firms for the period 1987 to 1989. The first model tests the relationship between R&D productivity and a vector of firm-specific characteristics. The second model tests the determinants of global market share. The empirical analysis reveals three findings. First, we find evidence that there are diminishing returns in the pharmaceutical R&D process. Second, we find that firm size has a positive effect on average R&D productivity and a positive impact on the marginal R&D productivity for plausible R&D staff sizes. And third, we find evidence that R&D productivity and the number of sales employees have a positive effect on the firm's global market share.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alexander, D., J. Flynn, and L. Linkins (forthcoming) ‘Estimates of the Demand for Ethical Pharmaceutical Drugs Across Countries and Time’,Applied Economics.
Cocks, D. (1975) ‘Product Innovation and the Dynamic Elements of Competition in the Ethical Pharmaceutical Industry’, in R. Helms (ed.)Drug Development and Marketing, 225–254. Washington, D.C.: The American Enterprise Institute.
Comanor, W. (1965) ‘Research and Technical Change in the Pharmaceutical Industry’,Review of Economics and Statistics,47, 182–190.
DiMasi, J., R. Hansen, H. Grabowski, and L. Lasagna (1991) ‘The Cost of Innovation in the Pharmaceutical Industry’,Journal of Health Economics,10, 107–142.
Glaxo Holdings, Plc. (various years)Annual Report, London: Glaxo Holdings, Plc.
Grabowski, H., J. Vernon, and L.G. Thomas (1978) ‘Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry’,Journal of Law and Economics,21, 133–163.
Japan Pharmaceutical Manufacturers Association (various years)Japan Data Book, Tokyo: Japan Pharmaceutical Manufacturers Association.
Jensen, E. (1987) ‘Research Expenditures and the Discovery of New Drugs’,Journal of Industrial Economics,36, 83–95.
Kmenta, J. (1986)Elements of Econometrics, 2nd Edition, New York: Macmillan Publishing Company, Inc.
PJB Publications, Limited (various years)Scrip Yearbook, London: PJB Publications, Limited.
Shearson Lehman Hutton (1990)Pharma Profiles, New York: Shearson Lehman Hutton.
Thomas, L.G. (1990) ‘Regulation and Firm Size: FDA Impacts on Regulation’,Rand Journal of Economics,21, 497–517.
Vernon, J. and Gusen, P. (1974) ‘Technical Change and Firm Size: The Pharmaceutical Industry’,Review of Economics and Statistics,56, 294–302.
Wiggins, S. (1981) ‘Product Quality Regulation and New Drug Introductions: Some Evidence from the 1970s’,Review of Economics and Statistics,63, 615–619.
Wiggins, S. (1983) ‘The Impact of Regulation on Pharmaceutical Research Expenditures: A Dynamic Approach’,Economic Inquiry,21, 115–128.
Wiggins, S. (1984) ‘The Effect of U.S. Pharmaceutical Regulation on New Introductions’, in B. Lindgren (ed.)Pharmaceutical Economics, 191–205. Stockholm: Swedish Institute for Health Economics.
Author information
Authors and Affiliations
Additional information
The views presented in this paper reflect those of the authors and do not necessarily reflect the views of the U.S. International Trade Commission or any of its individual commissioners. We thank William Comanor, Daniel Gropper, Daniel Hamermesh, Susan Pozo, Paul Thistle, and Mark Wheeler for their comments and suggestions on an earlier draft of this paper. We assume all responsibility for any errors contained herein.
Rights and permissions
About this article
Cite this article
Alexander, D.L., Flynn, J.E. & Linkins, L.A. Innovation, R&D productivity, and global market share in the pharmaceutical industry. Rev Ind Organ 10, 197–207 (1995). https://doi.org/10.1007/BF01029676
Issue Date:
DOI: https://doi.org/10.1007/BF01029676